A phase I/II trial of the proteasome inhibitor PS0341 (Velcade) [bortezomib] in combination with the anti-CD20 antibody, rituximab in patients with recurrent follicular lymphoma, mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinaemia (WM)
Latest Information Update: 07 Mar 2011
At a glance
- Drugs Bortezomib (Primary) ; Rituximab
- Indications Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2005 New trial record.